版本:
中国

BRIEF-ProQR receives fast track designation from FDA for QR-110

May 31 ProQR Therapeutics NV

* ProQR receives fast track designation from the FDA for QR-110 for leber’s congenital amaurosis type 10

* ‍top-line trial results are expected in 2018

* ‍QR-110 is currently in clinical development with planned phase 1/2 open-label trial (PQ-110-001)​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐